Sep. 4 at 7:53 PM
⏳️⌛️ Potential swing ideas 💡
✅️
$MAIA near 52wk low from recent high, recently secured European patent for cancer therapy, received FDA fast track designation for Ateganosie for its treatment of non-small cell lung cancer, recently announced agreement with ROCHE for cancer therapies, recently announced positive phase 2 clinical trial, Noble Financial price target
$14, company focuses on novel telomere-targeting drug called THIO (ateganosine), aimed at telemerase-positive cancers, especially non-small cell lunch cancer (NSCLC) and pediatric high-trade gliomas, operates multiple clinical-stage programs with a team based in Chicago, upcoming catalysts: 1) update clinical data on efficacy/safety for phase 2
✅️
$EEIQ recent offering price $.73 per share, recently entered into key agreement with MSM Unify, company focuses on providing educational services for international students heading to U.S, Canada, and UK,
🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
